首页> 美国卫生研究院文献>Journal of Korean Medical Science >The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea.
【2h】

The treatment of severe aplastic anemia: outcomes of bone marrow transplantation and immunosuppressive therapy in a single institution of Korea.

机译:严重再生障碍性贫血的治疗:在韩国一家机构中进行骨髓移植和免疫抑制治疗的结果。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study represents an analysis of 96 patients with severe aplastic anemia (SAA) treated in Seoul National University Hospital, Seoul, Korea between 1990 and 1999. Twenty-two patients were treated by allogeneic bone marrow transplantation (BMT) from HLA identical sibling donors and 74 by immunosuppressive therapy (IS) with antithymocyte globulin (ATG) or antilymphocyte globulin (ALG). There was no statistical difference between the two treatment groups in age, sex, disease duration, and previous transfusion amount. In the BMT group, grade II-IV acute graft versus host disease (GVHD) developed in 10% and chronic GVHD occurred in 33% of patient. Only one patient died from complication of transplantation (veno-occlusive disease). Of 74 patients who received IS treatment, 45% achieved a complete or partial response. Twenty patients died among IS treatment group. Major causes of death were hemorrhage (40%) and infection (55%). In the BMT group, the 5-yr overall survival (OS) was 95% after a median follow-up of 42 months. In the IS group, the 5-yr OS was 70% after a median follow-up of 49 months (p=0.04). In conclusion, the long-term survival rates of SAA in Koreans receiving BMT or IS were excellent compared with the Western data. Further evaluation on the prognosis of aplastic anemia in Asians should be done.
机译:本研究分析了1990年至1999年在韩国首尔国立首尔大学医院治疗的96例重度再生障碍性贫血(SAA)患者。22例患者接受了HLA同胞同种异体骨髓同种异体骨髓移植(BMT)的治疗74用抗胸腺细胞球蛋白(ATG)或抗淋巴细胞球蛋白(ALG)进行免疫抑制治疗(IS)。两组的年龄,性别,病程和先前输血量之间无统计学差异。在BMT组中,有10%的患者发生了II-IV级急性移植物抗宿主病(GVHD),而33%的患者发生了慢性GVHD。仅一名患者死于移植并发症(静脉阻塞性疾病)。在接受IS治疗的74例患者中,有45%达到了完全或部分缓解。 IS治疗组死亡20例。死亡的主要原因是出血(40%)和感染(55%)。在BMT组中,中位随访42个月后的5年总生存率(OS)为95%。在IS组中,中位随访49个月后的5年OS为70%(p = 0.04)。总之,与西方数据相比,接受BMT或IS的韩国人SAA的长期存活率极高。应该对亚洲人再生障碍性贫血的预后进行进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号